Clinical Trials Directory

A Phase 1 Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects With Advanced Cancer

This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Ixabepilone (oral formulation)

Phase: Phase 1


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Males and females, 18 or older - Histologically or cytologically confirmed diagnosis of solid tumor malignancy - Measurable or non-measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria - Karnofsky Performance Status (KPS) of 70-100 - Recovered from toxicities resulting from previous therapies

External Links

Footer Links: